Erythrocytes from patients with ST-elevation myocardial infarction induce cardioprotection through the purinergic P2Y 13 receptor and nitric oxide signaling

• Published in: Basic research in cardiology 2022-09, Vol.117 (1), p.46
• Main Authors: Jiao, Tong, Collado, Aida, Mahdi, Ali, Jurga, Juliane, Tengbom, John, Saleh, Nawzad, Verouhis, Dinos, Böhm, Felix, Zhou, Zhichao, Yang, Jiangning, Pernow, John
• Format: Article
• Language: English
• Subjects: Adenosine Triphosphate; Animals; Cyclic GMP-Dependent Protein Kinases; Erythrocytes - metabolism; Humans; Myocardial Infarction - prevention & control; Myocardial Infarction - therapy; Myocardial Reperfusion Injury - prevention & control; Myocardial Reperfusion Injury - therapy; NG-Nitroarginine Methyl Ester - pharmacology; Nitric Oxide - metabolism; Nitric Oxide Synthase; Purinergic P2 Receptor Antagonists; Rats; Receptors, Purinergic P2 - metabolism; Soluble Guanylyl Cyclase; ST Elevation Myocardial Infarction - metabolism
• ISSN: 0300-8428; 1435-1803
• DOI: 10.1007/s00395-022-00953-4

Red blood cells (RBCs) are suggested to play a role in cardiovascular regulation by exporting nitric oxide (NO) bioactivity and ATP under hypoxia. It remains unknown whether such beneficial effects of RBCs are protective in patients with acute myocardial infarction. We investigated whether RBCs from patients with ST-elevation myocardial infarction (STEMI) protect against myocardial ischemia-reperfusion injury and whether such effect involves NO and purinergic signaling in the RBCs. RBCs from patients with STEMI undergoing primary coronary intervention and healthy controls were administered to isolated rat hearts subjected to global ischemia and reperfusion. Compared to RBCs from healthy controls, RBCs from STEMI patients reduced myocardial infarct size (30 ± 12% RBC healthy vs. 11 ± 5% RBC STEMI patients, P